Experimental DMD drug shows promise in small early trial

NCT ID NCT06079736

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tested a new drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be fixed by skipping a part of their DNA called exon 51. The main goal was to see if the drug is safe and tolerable when given through a vein over several months, with a long-term follow-up. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • British Columbia Children's Hospital

    Vancouver, British Columbia, V6H1G9, Canada

  • CHU de Québec

    Québec, Quebec, G1V4G2, Canada

  • Children's Hospital of Eastern Ontario (CHEO)

    Ottawa, Ontario, K1H8L1, Canada

  • Stan Cassidy Centre for Rehabilitation

    Fredericton, New Brunswick, E3B0C7, Canada

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, M5G0A4, Canada

Conditions

Explore the condition pages connected to this study.